Pazopanib

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Pazopanib hydrochloride 216.7mg equivalent to Pazopanib 200 mg

Available from:

Teva Pharma (New Zealand) Limited

Dosage:

200 mg

Pharmaceutical form:

Film coated tablet

Composition:

Active: Pazopanib hydrochloride 216.7mg equivalent to Pazopanib 200 mg Excipient: Hypromellose Iron oxide red Macrogol 400 Magnesium stearate Microcrystalline cellulose Polysorbate 80 Povidone Purified water   Sodium starch glycolate Titanium dioxide

Prescription type:

Prescription

Therapeutic indications:

Renal cell carcinoma (RCC) Pazopanib (Teva) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (RCC).

Product summary:

Package - Contents - Shelf Life: Blister pack, PVC/PVdC/PE-Al - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PVdC/PE-Al - 90 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with PP CRC - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with PP CRC - 90 tablets - 36 months from date of manufacture stored at or below 25°C

Authorization date:

2022-04-11